BioBUZZ - You're Fired

Research evidence excerpt

BioBUZZ - You're Fired

Biotechnology

EQUITY RESEARCH Industry Report

May 16, 2026

Prices are as of 05/15/26.

Research Analysts: Editor's note: BioBUZZ is a weekly roundup of our discussions with investors.

Eric Schmidt We believe a better understanding of buyside sentiment can facilitate better

212-294-7724 investment decision-making.

Eric.Schmidt@cantor.com

Josh Schimmer

310-282-6513 The past week was a bit quieter with earnings winding down, fewer data

Josh.Schimmer@cantor.com releases, and, for the first time in a while, no M&A. But there were plenty

Prakhar Agrawal of things people wanted to talk about, so let's get right into the chatter. 212-610-3614

Prakhar.Agrawal@cantor.com

Olivia Brayer Saunders

212-428-5907 Biotech - what's next for the FDA? After much speculation, the

Olivia.Brayer@cantor.com announcement of Dr. Makary's departure was fairly anticlimactic. And while

Carter Gould

212-915-1794 no one is going to miss him, there are questions about whether anything

Carter.Gould@cantor.com can really change at the FDA, at least as long as RFK Jr. remains in his seat.

Kristen Kluska

212-915-1927 ●Some of what is to come will depend upon the next FDA

Kristen.Kluska@cantor.com Commissioner. Our friends at No Patient Left Behind have circulated Steve Seedhouse

212-915-1240 a petition calling for the appointment of Dr. Richard Pazdur (HERE).

Steve.Seedhouse@cantor.com Presumably, this was done with Dr. Pazdur's consent.

Yanni Souroutzidis

929-730-2656 ●Most important, in our view, is that whoever is appointed

Yanni.Souroutzidis@cantor.com Commissioner acts, well, like a Commissioner. This means protecting

Pete Stavropoulos, Ph.D. the Agency from political intervention, supporting the review and 212-915-1966